Nxera Pharma boosts Japan-APAC portfolio and pipeline as 2025 restructuring sharpens growth focus

Sosei Group ( (JP:4565) ) just unveiled an update.

Nxera Pharma reported a year of disciplined execution in 2025, strengthening its commercial base in Japan and APAC while advancing a maturing pipeline. The company’s aneurysmal subarachnoid haemorrhage drug PIVLAZ® consolidated its position as the standard of care in Japan, driving market share to 74% and 6.8% year-on-year net sales growth, while insomnia therapy QUVIVIQ™ delivered a more than threefold sales increase supported by expanded Asian manufacturing capacity to secure supply and improve margins.

Operationally, Nxera pushed several partnered assets forward, including Phase 3 initiation of Neurocrine’s NBI-‘568 muscarinic agonist and encouraging Phase 1 oncology data for HTL’732, generating around US$35 million in milestones and a further US$3.6 million from Centessa for OX2R agonist ORX142. The company undertook a focused restructuring to concentrate investment on high-potential platforms, regain full rights to its Phase 2–ready GPR52 schizophrenia program for potential partnering, launch a new proprietary obesity and metabolic disease pipeline and expand its late- and commercial-stage portfolio in Japan/APAC through licensing vamorolone for Duchenne Muscular Dystrophy and progressing daridorexant toward South Korean approval.

The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.

More about Sosei Group

Nxera Pharma Co., Ltd., listed on the Tokyo Stock Exchange, is a biopharmaceutical company focused on developing and commercializing innovative medicines, particularly in neuroscience and specialty indications. The company has a growing commercial footprint in Japan and the broader Asia-Pacific region, with marketed products for cerebral vasospasm prevention and insomnia, and a pipeline spanning muscarinic agonists, oncology, metabolic disease and rare neuromuscular disorders.

Average Trading Volume: 875,488

Technical Sentiment Signal: Sell

Current Market Cap: Yen80.36B

See more insights into 4565 stock on TipRanks’ Stock Analysis page.